Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLBS119 for COVID-19 induced pulmonary damage
NCT04522817Phase 1Withdrawn
- Sponsor
- Lisata Therapeutics
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous peripheral blood-derived CD34+ cells in coronavirus disease 2019 (COVID-19), sponsored by Lisata Therapeutics. Primary endpoint: Adverse events at 6 months. Planned start Oct 2020; status: withdrawn.
02
Drugs
autologous peripheral blood-derived CD34+ cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04522817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522817.